Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C27H31NO3.ClH |
| Molecular Weight | 454.001 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC2=C(CCN(C)C(CCC3=CC=CC=C3)CC4=C2C(O)=C(OC)C=C4)C=C1
InChI
InChIKey=JTGDTQLVMHZOHX-UHFFFAOYSA-N
InChI=1S/C27H31NO3.ClH/c1-28-16-15-20-10-13-23(30-2)18-24(20)26-21(11-14-25(31-3)27(26)29)17-22(28)12-9-19-7-5-4-6-8-19;/h4-8,10-11,13-14,18,22,29H,9,12,15-17H2,1-3H3;1H
Asocainol is a rather efficient antiarrhythmic agent that has the effects of both class Ia and class IV antiarrhythmic drugs. Asocainol interfere with the sodium channel and lengthens the action potential. Besides that, Asocainol decreases conduction through the AV node, and shorten phase two (the plateau) of the cardiac action potential. Asocainol reduce the contractility of the heart, so may be inappropriate in heart failure. Asocainol is an effective antiarrhythmic agent in a variety of animal arrhythmia models and species.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
293-842-5
Created by
admin on Mon Mar 31 22:43:09 GMT 2025 , Edited by admin on Mon Mar 31 22:43:09 GMT 2025
|
PRIMARY | |||
|
8VX5A020BS
Created by
admin on Mon Mar 31 22:43:09 GMT 2025 , Edited by admin on Mon Mar 31 22:43:09 GMT 2025
|
PRIMARY | |||
|
170357
Created by
admin on Mon Mar 31 22:43:09 GMT 2025 , Edited by admin on Mon Mar 31 22:43:09 GMT 2025
|
PRIMARY | |||
|
91574-89-9
Created by
admin on Mon Mar 31 22:43:09 GMT 2025 , Edited by admin on Mon Mar 31 22:43:09 GMT 2025
|
PRIMARY | |||
|
DTXSID40919647
Created by
admin on Mon Mar 31 22:43:09 GMT 2025 , Edited by admin on Mon Mar 31 22:43:09 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
